Financhill
Sell
46

REGN Quote, Financials, Valuation and Earnings

Last price:
$605.13
Seasonality move :
8.74%
Day range:
$597.92 - $617.52
52-week range:
$520.50 - $1,211.20
Dividend yield:
0.29%
P/E ratio:
15.39x
P/S ratio:
4.90x
P/B ratio:
2.22x
Volume:
1.1M
Avg. volume:
1.3M
1-year change:
-39.17%
Market cap:
$65.3B
Revenue:
$14.2B
EPS (TTM):
$39.28

Analysts' Opinion

  • Consensus Rating
    Regeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $797.21, Regeneron Pharmaceuticals has an estimated upside of 31.85% from its current price of $604.62.
  • Price Target Downside
    According to analysts, the lowest downside price target is $535.00 representing 11.52% downside risk from its current price of $604.62.

Fair Value

  • According to the consensus of 18 analysts, Regeneron Pharmaceuticals has 31.85% upside to fair value with a price target of $797.21 per share.

REGN vs. S&P 500

  • Over the past 5 trading days, Regeneron Pharmaceuticals has overperformed the S&P 500 by 8.04% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Regeneron Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Regeneron Pharmaceuticals revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Regeneron Pharmaceuticals reported revenues of $3B.

Earnings Growth

  • Regeneron Pharmaceuticals has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Regeneron Pharmaceuticals reported earnings per share of $7.27.
Enterprise value:
58.9B
EV / Invested capital:
1.88x
Price / LTM sales:
4.90x
EV / EBIT:
11.71x
EV / Revenue:
4.18x
PEG ratio (5yr expected):
0.96x
EV / Free cash flow:
19.89x
Price / Operating cash flow:
23.29x
Enterprise value / EBITDA:
10.66x
Gross Profit (TTM):
$12.1B
Return On Assets:
12.28%
Net Income Margin (TTM):
31.94%
Return On Equity:
15.7%
Return On Invested Capital:
14.69%
Operating Margin:
19.54%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $12.4B $13.1B $14.1B $3.1B $3B
Gross Profit $10.8B $11.3B $12.1B $2.7B $2.6B
Operating Income $4.4B $3.9B $3.8B $751.4M $591.7M
EBITDA $5.1B $4.5B $5.5B $830.9M $1B
Diluted EPS $36.80 $33.85 $39.28 $6.27 $7.27
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $10.1B $14.3B $16.9B $18.9B $17.6B
Total Assets $17.8B $26.3B $30.1B $34.4B $37.5B
Current Liabilities $3.2B $3B $3.1B $3.6B $3.6B
Total Liabilities $5.8B $6.4B $6.6B $7.4B $8.2B
Total Equity $12B $19.9B $23.5B $27B $29.4B
Total Debt $2B $2B $2B $2B $2B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations $4.3B $4.7B $4B $1.5B $1B
Cash From Investing -$2.3B -$4.6B -$133.5M -$1.7B $647.5M
Cash From Financing -$1.4B -$1.4B -$3.3B $47.1M -$1.1B
Free Cash Flow $2.5B $3.9B $3B $1.4B $773.6M
REGN
Sector
Market Cap
$65.3B
$35M
Price % of 52-Week High
49.92%
43.76%
Dividend Yield
0.29%
0%
Shareholder Yield
4.66%
-0.59%
1-Year Price Total Return
-39.17%
-41.98%
Beta (5-Year)
0.427
0.659
Dividend yield:
0.29%
Annualized payout:
$0.00
Payout ratio:
2.09%
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $589.55
200-day SMA
Sell
Level $811.27
Bollinger Bands (100)
Sell
Level 592.71 - 707.01
Chaikin Money Flow
Buy
Level 84.2M
20-day SMA
Buy
Level $584.57
Relative Strength Index (RSI14)
Buy
Level 54.29
ADX Line
Buy
Level 19.89
Williams %R
Sell
Level -13.2962
50-day SMA
Buy
Level $602.36
MACD (12, 26)
Sell
Level -0.30
25-day Aroon Oscillator
Buy
Level 36
On Balance Volume
Neutral
Level 36.8M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (8.0143)
Buy
CA Score (Annual)
Level (1.5975)
Buy
Beneish M-Score (Annual)
Level (-2.3083)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-4.5238)
Buy
Piotroski F Score (Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (9)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Stock Forecast FAQ

In the current month, REGN has received 14 Buy ratings 4 Hold ratings, and 0 Sell ratings. The REGN average analyst price target in the past 3 months is $797.21.

  • Where Will Regeneron Pharmaceuticals Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Regeneron Pharmaceuticals share price will rise to $797.21 per share over the next 12 months.

  • What Do Analysts Say About Regeneron Pharmaceuticals?

    Analysts are divided on their view about Regeneron Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Regeneron Pharmaceuticals is a Sell and believe this share price will drop from its current level to $535.00.

  • What Is Regeneron Pharmaceuticals's Price Target?

    The price target for Regeneron Pharmaceuticals over the next 1-year time period is forecast to be $797.21 according to 18 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.

  • Is REGN A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Regeneron Pharmaceuticals is a Buy. 14 of 18 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of REGN?

    You can purchase shares of Regeneron Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Regeneron Pharmaceuticals shares.

  • What Is The Regeneron Pharmaceuticals Share Price Today?

    Regeneron Pharmaceuticals was last trading at $605.13 per share. This represents the most recent stock quote for Regeneron Pharmaceuticals. Yesterday, Regeneron Pharmaceuticals closed at $604.62 per share.

  • How To Buy Regeneron Pharmaceuticals Stock Online?

    In order to purchase Regeneron Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is GlobalFoundries On The Verge Of A Breakout?
Is GlobalFoundries On The Verge Of A Breakout?

GLOBALFOUNDRIES Inc. (NASDAQ:GFS) is as a semiconductor foundry whose chips…

Is Dick’s Sporting Goods Buying Foot Locker Smart?
Is Dick’s Sporting Goods Buying Foot Locker Smart?

Last week, Dick’s Sporting Goods (NYSE:DKS) announced that it would…

Is Ginkgo Bioworks Stock a Good Buy?
Is Ginkgo Bioworks Stock a Good Buy?

Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
58
WIX alert for May 22

Wix.com [WIX] is up 1.4% over the past day.

Buy
81
DY alert for May 22

Dycom Industries [DY] is down 1.28% over the past day.

Sell
50
FICO alert for May 22

Fair Isaac [FICO] is up 1.12% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock